Udenafil
- Generic Name
- Udenafil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H36N6O4S
- CAS Number
- 268203-93-6
- Unique Ingredient Identifier
- L5IB4XLY36
- Background
Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada.
- Indication
Investigated for use/treatment in erectile dysfunction and hypertension.
- Associated Conditions
- Erectile Dysfunction
- Associated Therapies
- -
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT01553721
- Locations
- π°π·
Pusan national University Hospital, Pusan, Korea, Republic of
π°π·Chonnam National University Hospital, Gwang-ju, Korea, Republic of
π°π·Seoul National University Hospital, Seoul, Chongno-gu, 28 Yongon-dong, Korea, Republic of
The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Kyungpook National University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01421940
- Locations
- π°π·
Kyungpook National University Medical Center, Daegu, Korea, Republic of
The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
- Conditions
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2011-06-20
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT01364181
- Locations
- π°π·
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
Efficacy and Safety Study of Udenafil Tablets in Erectile Dysfunction.
- First Posted Date
- 2011-02-28
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Abdi Ibrahim Ilac San. ve Tic A.S.
- Target Recruit Count
- 118
- Registration Number
- NCT01305083
Phase I Study to Investigate the Alcohol Interaction of DA8159
- Conditions
- Interventions
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2010-11-16
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT01241032
- Locations
- π°π·
Asan Medical Center, Seoul, Korea, Republic of
Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients
- Conditions
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2010-11-02
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT01231997
- Locations
- π°π·
Asan Medical Center, Seoul, Korea, Republic of
Effect of Udenafil on Spermatogenesis
- Conditions
- Interventions
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 239
- Registration Number
- NCT01230541
- Locations
- πΊπΈ
Warner Chilcott Investigational Site, Spokane, Washington, United States
Treatment of Erectile Dysfunction I
- First Posted Date
- 2009-12-22
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 618
- Registration Number
- NCT01037244
- Locations
- πΊπΈ
Warner Chilcott Investigational Site, Spokane, Washington, United States
Treatment of Erectile Dysfunction II
- First Posted Date
- 2009-12-22
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 601
- Registration Number
- NCT01037218
- Locations
- πΊπΈ
Warner Chilcott Investigational Site, Mountlake Terrace, Washington, United States
A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Dong-A Pharmaceutical Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT00956306
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.